ABUS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ABUS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Arbutus Biopharma's gross profit for the three months ended in Sep. 2024 was $1.34 Mil. Arbutus Biopharma's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $6.74 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Arbutus Biopharma's gross profit for the three months ended in Sep. 2024 was $1.34 Mil. Arbutus Biopharma's Revenue for the three months ended in Sep. 2024 was $1.34 Mil. Therefore, Arbutus Biopharma's Gross Margin % for the quarter that ended in Sep. 2024 was N/A%.
Arbutus Biopharma had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage
The historical data trend for Arbutus Biopharma's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Gross Profit | Get a 7-Day Free Trial | 6.01 | 6.91 | 10.99 | 39.02 | 18.14 |
Arbutus Biopharma Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Gross Profit | Get a 7-Day Free Trial | 4.66 | 2.15 | 1.53 | 1.73 | 1.34 |
For the Biotechnology subindustry, Arbutus Biopharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Gross Profit distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Arbutus Biopharma's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit (A: Dec. 2023 ) | = | Revenue | - | Cost of Goods Sold |
= | 18.141 | - | 0 | |
= | 18.14 |
Arbutus Biopharma's Gross Profit for the quarter that ended in Sep. 2024 is calculated as
Gross Profit (Q: Sep. 2024 ) | = | Revenue | - | Cost of Goods Sold |
= | 1.339 | - | 0 | |
= | 1.34 |
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.74 Mil.
Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
Arbutus Biopharma's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as
Gross Margin % (Q: Sep. 2024 ) | = | Gross Profit (Q: Sep. 2024 ) | / | Revenue (Q: Sep. 2024 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 1.34 | / | 1.339 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Arbutus Biopharma (NAS:ABUS) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Arbutus Biopharma had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage
Thank you for viewing the detailed overview of Arbutus Biopharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Keith S Manchester | director | C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L |
Karen Sims | officer: Chief Medical Officer | 701 VETERANS CIRCLE, WARMINSTER PA 18974 |
David C Hastings | officer: Chief Financial Officer | C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8 |
Michael J. Mcelhaugh | officer: Chief Business Officer | C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902 |
Michael J. Sofia | officer: Chief Scientific Officer | C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8 |
Melissa Rewolinski | director | 9000 STATE ROAD, PHILADELPHIA PA 19136 |
J. Christopher Naftzger | officer: General Counsel and CCO | 633 LOWTHER ROAD, LEWISBERRY PA 17339 |
Tram Tran | director | C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Eric Venker | director | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
James R Meyers | director | GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Andrew Cheng | director | 170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080 |
Myrtle S Potter | director | 10 FINDERNE AVE, BRIDGEWATER NJ 08807 |
William H. Collier | director, officer: President and CEO | C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974 |
Elizabeth Howard | officer: Executive VP & General Counsel | 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8 |
From GuruFocus
By GuruFocus Research • 05-02-2024
By Business Wire • 05-17-2024
By Marketwired • 11-26-2024
By Marketwired • 05-29-2024
By Marketwired • 04-18-2024
By Marketwired • 08-01-2024
By Marketwired • 11-06-2024
By GuruFocus Research • 05-03-2024
By Marketwired • 10-15-2024
By GuruFocus News • 11-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.